Direct Stenting With the TAXUS Liberté Drug-Eluting Stent. Results From the TAXUS ATLAS DIRECT STENT Study

26Citations
Citations of this article
16Readers
Mendeley users who have this article in their library.

Abstract

Objectives: This study was conducted to determine whether direct stenting with TAXUS Liberté is noninferior to stenting after pre-dilation. Background: Direct stenting is performed in approximately 30% of patients, but data on clinical and angiographic outcomes with drug-eluting stents are limited. Methods: The TAXUS ATLAS DIRECT STENT is a single-arm, multicenter study that enrolled patients with de novo coronary lesions visually estimated to be 10 to 28 mm in length in vessels 2.5 to 4.0 mm in diameter. The control group is the quantitative coronary angiography (QCA) subset of the TAXUS ATLAS trial, which used identical inclusion and exclusion criteria but mandated pre-dilation. The primary end point is 9-month analysis-segment percent diameter stenosis (%DS). Results: Baseline patient characteristics were similar between the groups. On QCA analysis, significantly shorter lesions with larger lumen diameter and less calcification were observed in the direct stent group. Direct stenting was successful in 97.6% of patients and was associated with a shorter procedure time and fewer complications. Follow-up %DS was noninferior for direct stent (26.41%) versus pre-dilation (29.14%) with a 1-sided 95% confidence interval of the difference between the groups (-0.34%) well below the pre-specified noninferiority margin (6.75%). Additionally, significantly lower restenosis (5.9% vs. 11.4%, p = 0.0229) and target lesion revascularization (TLR) 2.9% vs. 7.8%, p = 0.0087) rates were seen for direct stent versus pre-dilation. Conclusions: Direct stenting of TAXUS Liberté is feasible and highly successful in carefully selected lesions. Direct stenting is noninferior to stenting after pre-dilation on the basis of %DS and can significantly reduce procedural time, procedural complications, and possibly angiographic restenosis and TLR. (TAXUS Liberté-SR Paclitaxel-Eluting Coronary Stent System; NCT00371423). © 2008 American College of Cardiology Foundation.

Cite

CITATION STYLE

APA

Ormiston, J. A., Mahmud, E., Turco, M. A., Popma, J. J., Weissman, N., Cannon, L. A., … Baim, D. S. (2008). Direct Stenting With the TAXUS Liberté Drug-Eluting Stent. Results From the TAXUS ATLAS DIRECT STENT Study. JACC: Cardiovascular Interventions, 1(2), 150–160. https://doi.org/10.1016/j.jcin.2008.01.003

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free